About Arbor Biotechnologies
Arbor Biotechnologies is a company based in Cambridge (United States) founded in 2016 by David Scott and Winston Yan. Arbor Biotechnologies has raised $304.1 million across 4 funding rounds from investors including Vertex Pharmaceuticals, T. Rowe Price and Temasek. The company has 117 employees. Arbor Biotechnologies has completed 1 acquisition, including Serendipity Biosciences. Arbor Biotechnologies offers products and services including Gene Editing Toolbox and Pipeline Products. Arbor Biotechnologies operates in a competitive market with competitors including Singleron, Octant, Diagenode, Factor Bioscience and Novomics, among others.
- Total Equity Funding$304.1M (USD)
in 4 rounds
- InvestorsVertex Pharmaceuticals
& 26 more
- Employee Count117
- Investments & Acquisitions
Products & Services of Arbor Biotechnologies
Arbor Biotechnologies offers a comprehensive portfolio of products and services, including Gene Editing Toolbox and Pipeline Products.
Provides tools for developing next-generation gene editing treatments.
Advances gene editing for various genetic disease applications.
Funding Insights of Arbor Biotechnologies
Arbor Biotechnologies has successfully raised a total of $304.1M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $304.1M
- Total Rounds 4
- First Round $15.6M
(Aug 2017)
- Investors Count 27
All 4 funding rounds of Arbor Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | – | Series C | – | – | |
| Mar 2025 | $73.5M | Series C | – | Arch Venture Partners, TCG Crossover | |
| Nov 2021 | $215M | Series B | – | Temasek, TCG Crossover | |
| Aug 2017 | $15.6M | Series A | – | Keith Crandell, Annie Hazlehurst |
27 investors in total: 25 institutional and 2 angel.
Investors in Arbor Biotechnologies
Arbor Biotechnologies has secured backing from 27 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Vertex Pharmaceuticals, T. Rowe Price and Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
- | – | tcgcrossover.com | - | |
PE firm investing in South Korea and the US | – | partnersi.co.kr | Seoul, South Korea | |
Private equity and hedge fund investments in healthcare are managed. | – | ally-bridge.com | Hong Kong, China | |
Deep Track Capital is engaged in biotechnology investment activities. | – | deeptrackcapital.com | Greenwich, United States | |
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors | – | gpv.com | San Francisco, United States | |
Health tech startups are invested in by Illumina Ventures. | – | illuminaventures.com | Foster City, United States | |
Venture capital firm focused on multiple sectors | – | taocap.com | Marlborough, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom |
Investor details for Arbor Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arbor Biotechnologies
50 people are tracked at Arbor Biotechnologies (20 in leadership, 6 in board & advisors, 24 in team); the tracked headcount is 117.
| Name | Role | Group |
|---|---|---|
David Scott | Co-Founder | Leadership |
Winston Yan | Co-Founder | Leadership |
Devyn Smith | CEO | Leadership |
David Cheng | Chief Technology Officer | Leadership |
John Murphy | Chief Scientific Officer | Leadership |
Tia Ditommaso | Vice President, Lead Identification | Leadership |
Lee Ann Marchionna | Chief People Officer | Leadership |
Pam Stetkiewicz | COO | Leadership |
Ray Bourdeau | Director, Delivery & Process Sciences | Leadership |
Dan Ory | CMO | Leadership |
Noah Jakimo | Associate Director, Head Of Computational Design | Leadership |
Jennifer Casagrande | Director Clinical Operations | Leadership |
Guyan Zhang | Sr. Director Of Finance, Financial Controller | Leadership |
Florie Borel | Senior Director - Head Of In Vivo Pharmacology | Leadership |
Yurong Xin | Head Of Computational Biology And Data Science | Leadership |
Anthony Garrity | Associate Director | Leadership |
Mathew Lindenmayer | Vice President, Finance | Leadership |
Priscilla Davidson Negraes | Associate Director, CNS Therapies | Leadership |
Catherine Symonds | Vice President Of Program And Portfolio Management | Leadership |
Karen Wood | Senior Director, Head Of Patents & Patent Strategy | Leadership |
30 more people are available in the full profile.
Complete people profiles for Arbor Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arbor Biotechnologies
Arbor Biotechnologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Serendipity Biosciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene-editing technology and genetic medicines are developed for therapeutic uses. | serendipitybiosciences.tcc.mode | – | 0 | May 2024 | •••• |
Complete acquisition details for Arbor Biotechnologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Arbor Biotechnologies
4 dated milestones of Arbor Biotechnologies across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Arbor Biotechnologies is founded.
- Funding First funding round of $15.6M.
- Acquisition Acquires Serendipity Biosciences.
- Funding Latest funding round, Series C,.
Competitors of Arbor Biotechnologies
Arbor Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Singleron, Octant, Diagenode, Factor Bioscience and Novomics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| singleron.bio | 2018 | Hagen, Germany | $84.48M | – | Developer of single-cell multi-omics platform for clinical research and molecular diagnosis | |
| octant.bio | 2017 | Los Angeles, United States | $110M | 63 | Human cell interaction platform is provided for drug discovery. | |
| diagenode.com | 2003 | Seraing, Belgium | $8.45M | 99 | Reagents and kits for epigenetics sequencing solutions are developed. | |
| factor.bio | 2011 | Cambridge, United States | $1M | – | Genomic technologies are developed to treat diseases and enhance health. | |
| novomics.com | 2010 | Seoul, South Korea | $3.41M | – | Molecular diagnosis systems for cancer treatment are developed. | |
| genomicvision.com | 2004 | Bagneux, France | $8.3M | – | Single DNA molecules are analyzed via nanotechnology for cancer diagnostics. | |
| nonacus.com | 2015 | Birmingham, United Kingdom | – | 13 | Provides NGS panels, kits, and services for genomic analysis in healthcare research. |
Detailed competitors of Arbor Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arbor Biotechnologies
The website of Arbor Biotechnologies (arbor.bio) receives about 5.9K visits a month and ranks #3,071,285 among all websites worldwide, #4,060 in Biotechnology and Pharmaceuticals.
- Monthly visits5.9K
▼ 6.1% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,071,285
among all websites
- Category rank#4,060
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.9
- Average visit39 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Arbor Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arborbiosci.com | 100% | 14.3K | #1,335,717 | View details |
Latest news on Arbor Biotechnologies
Complete news archive for Arbor Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Arbor Biotechnologies
10 companies that operate in the same segment as Arbor Biotechnologies (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Arbor Biotechnologies
Arbor Biotechnologies was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Arbor Biotechnologies is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Arbor Biotechnologies is a funded company, having raised a total of $304.1M across 4 funding rounds to date. The company's 1st funding round was a Series A of $15.6M, raised on Aug 2017.
Arbor Biotechnologies has 117 employees.
Arbor Biotechnologies was founded in 2016 in Cambridge, United States, within the biotechnology sector. A platform is operated that integrates artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening to facilitate protein discovery. A new CRISPR enzyme has been identified through this platform. Operations focus on advancing genomic tools for research and therapeutic development in the life sciences field.
Arbor Biotechnologies offers Gene Editing Toolbox and Pipeline Products.
Arbor Biotechnologies has made 1 acquisition, including Serendipity Biosciences.
Arbor Biotechnologies has 27 investors. Key investors include Vertex Pharmaceuticals, T. Rowe Price, Temasek, Janus Henderson Investors, and Piper Sandler.
Arbor Biotechnologies operates through Arbor Biotechnologies, Inc..